377220 — From Bio Share Price
Last trade - 00:00- KR₩16bn
- KR₩49bn
- KR₩72bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.69 | ||
| Price to Tang. Book | 0.71 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.22 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -69.3% | ||
| Return on Equity | -60.62% | ||
| Operating Margin | -23.07% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 135,103.27 | 99,330.4 | 66,723.97 | 67,181.88 | 72,162.17 | n/a | n/a | -7.76% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | -74.67 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
From Bio Co Ltd is a Korea-based company principally engaged in the health functional food business. The Company is engaged in the production and sale of functional foods related to joint health, stomach health, eye health, and sleep health and others. In addition, the Company is engaged in the manufacture and sale of wild mango and other diet food, creams, shampoos, soaps and other products.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- June 26th, 2006
- Public Since
- September 28th, 2021
- No. of Shareholders
- 20,869
- No. of Employees
- 160
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 5,662,000
- Address
- FB tower, YONGIN, 17108
- Web
- https://frombio-company.co.kr/
- Phone
- +82 318955252
- Auditors
- Daejoo Accounting Corp.
Latest News for 377220
Upcoming Events for 377220
From Bio Co Ltd Extraordinary Shareholders Meeting
From Bio Co Ltd Annual Shareholders Meeting
Similar to 377220
Asia Seed
Korea Exchange - KOSDAQ
B2En
Korea Exchange - KOSDAQ
Bifido
Korea Exchange - KOSDAQ
Bio Port Korea
Korea Exchange - KOSDAQ
BL PharmTech
Korea Exchange - KOSDAQ
FAQ
As of Today at 02:44 UTC, shares in From Bio are trading at KR₩2,840. This share price information is delayed by 15 minutes.
Shares in From Bio last closed at KR₩2,840 and the price had moved by -62.08% over the past 365 days. In terms of relative price strength the From Bio share price has underperformed the FTSE Developed Asia Pacific Index by -72.31% over the past year.
There is no consensus recommendation for this security.
Find out moreFrom Bio does not currently pay a dividend.
From Bio does not currently pay a dividend.
From Bio does not currently pay a dividend.
To buy shares in From Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩2,840, shares in From Bio had a market capitalisation of KR₩16bn.
Here are the trading details for From Bio:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 377220
Based on an overall assessment of its quality, value and momentum From Bio is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like From Bio. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -57.66%.
As of the last closing price of KR₩2,840, shares in From Bio were trading -44.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The From Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩2,840.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on From Bio's directors